Raloxifene 60 - Dragon Pharma

First approved by the FDA in 1997 Raloxifene hydrochloride was developed by Eli Lilly & Company to handle osteoporosis in postmenopausal women. Later it gained one more approval for reducing the risk of invasive breast cancer. Raloxifene selectively stimulates estrogen receptors in bone while blocking them in breast tissue, making it a widely used drug in over 50 countries under the brand name Evista.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Raloxifene 60 by Dragon Pharma, consult with your doctor or healthcare professional.